Related Experiment Video

Updated: May 5, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic

Andrea E Bochem1, Diederik F van Wijk, Adriaan G Holleboom

  • 1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

European Heart Journal
|November 9, 2012
PubMed

Insights

Individuals with ATP-binding cassette transporter A1 (ABCA1) mutations have lower HDL-C and increased carotid artery atherosclerosis, suggesting a higher cardiovascular disease risk. These findings support ABCA1-focused therapeutic strategies.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Biochemistry

Background:

  • Low high-density lipoprotein cholesterol (HDL-C) is a significant risk factor for cardiovascular disease (CVD).
  • Mutations in ATP-binding cassette transporter A1 (ABCA1), a key regulator of HDL-C, were not previously linked to CVD risk in cohort studies.
  • Understanding the impact of ABCA1 dysfunction on atherosclerosis is crucial for CVD prevention.

Purpose of the Study:

  • To investigate the consequences of reduced HDL-C due to ATP-binding cassette transporter A1 (ABCA1) dysfunction on atherosclerotic vascular disease in carotid arteries.
  • To assess the relationship between ABCA1 mutations, HDL-C levels, and carotid artery wall characteristics.

Main Methods:

  • 3.0 Tesla magnetic resonance imaging (MRI) was used to measure carotid artery parameters in 36 carriers of functional ABCA1 mutations and 36 normolipidemic controls.
  • Measurements included mean wall area, mean wall thickness, and normalized wall index.
  • Statistical analyses were performed, adjusting for multiple cardiovascular risk factors.

Main Results:

  • ABCA1 mutation carriers exhibited 42% lower HDL-C levels compared to controls (P < 0.001).
  • Carriers showed significantly larger mean wall area (P = 0.02), mean wall thickness (P = 0.005), and normalized wall index (P = 0.005).
  • These differences remained significant after adjusting for major cardiovascular risk factors (P = 0.002).

Conclusions:

  • Loss-of-function ABCA1 mutations are associated with increased carotid artery atherosclerotic burden, implying a higher CVD risk.
  • Further research is needed to fully understand ABCA1's protective role against atherosclerosis.
  • These findings support developing strategies to enhance ABCA1 activity in patients with existing CVD.
Abstract

More Related Videos

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.6K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

577

Related Concept Videos

ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.7K
The ADP/ATP Carrier Protein01:42

The ADP/ATP Carrier Protein

ADP/ATP carrier or AAC protein is the most abundant carrier protein in the inner mitochondrial membrane. It transports large quantities of ADP and ATP, equivalent to the average human body weight, every day. Among other transporters, ACC protein is one of the best-studied members of the mitochondrial carrier protein family. The ADP/ATP carrier protein comprises two transmembrane helices connected to a loop and a single alpha-helix on the matrix side. It switches between two conformational...
3.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747